Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
KURA

Kura Oncology

$18.70

0.2 (1.08%)

, CELG

Celgene

$79.45

1.74 (2.24%)

07:46
06/20/18
06/20
07:46
06/20/18
07:46
Hot Stocks
Kura Oncology appoints John Farnam as COO »

Kura Oncology (KURA) …

KURA

Kura Oncology

$18.70

0.2 (1.08%)

CELG

Celgene

$79.45

1.74 (2.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Tuesday
CELG

Celgene

$79.45

1.74 (2.24%)

16:32
06/19/18
06/19
16:32
06/19/18
16:32
Hot Stocks
Celgene names Jonathan Biller as General Counsel »

Celgene announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLUE

Bluebird Bio

$176.50

-6.25 (-3.42%)

, CELG

Celgene

$77.71

-0.38 (-0.49%)

07:48
06/19/18
06/19
07:48
06/19/18
07:48
Upgrade
Bluebird Bio, Celgene rating change at Evercore ISI »

Bluebird Bio upgraded to…

BLUE

Bluebird Bio

$176.50

-6.25 (-3.42%)

CELG

Celgene

$77.71

-0.38 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GILD

Gilead

$69.05

-1.16 (-1.65%)

04:55
06/19/18
06/19
04:55
06/19/18
04:55
Conference/Events
Gilead management to meet with UBS »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 25

    Jun

Monday
CELG

Celgene

$77.18

-0.91 (-1.17%)

11:46
06/18/18
06/18
11:46
06/18/18
11:46
Upgrade
Celgene rating change at Standpoint Research »

Celgene upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a week ago
GILD

Gilead

$71.17

0.45 (0.64%)

08:41
06/15/18
06/15
08:41
06/15/18
08:41
Conference/Events
Gilead management to meet with UBS »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 25

    Jun

GILD

Gilead

$71.17

0.45 (0.64%)

, ALXN

Alexion

$120.21

1.97 (1.67%)

07:38
06/15/18
06/15
07:38
06/15/18
07:38
Recommendations
Gilead, Alexion, Vertex analyst commentary at Oppenheimer »

Large-cap biotech…

GILD

Gilead

$71.17

0.45 (0.64%)

ALXN

Alexion

$120.21

1.97 (1.67%)

VRTX

Vertex

$155.00

3.15 (2.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 25

    Jun

  • 25

    Jun

  • 26

    Jun

  • 27

    Jun

XLRN

Acceleron

$36.12

0.19 (0.53%)

, CELG

Celgene

$78.39

1.01 (1.31%)

07:15
06/15/18
06/15
07:15
06/15/18
07:15
Hot Stocks
Acceleron announces updated results from luspatercept Phase 2 trials at EHA »

Acceleron (XLRN)…

XLRN

Acceleron

$36.12

0.19 (0.53%)

CELG

Celgene

$78.39

1.01 (1.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GSK

GlaxoSmithKline

$41.15

(0.00%)

, GILD

Gilead

$70.72

(0.00%)

09:23
06/14/18
06/14
09:23
06/14/18
09:23
Hot Stocks
GSK two-drug HIV regimen meets primary endpoint in Phase III study »

GlaxoSmithKline's…

GSK

GlaxoSmithKline

$41.15

(0.00%)

GILD

Gilead

$70.72

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jun

  • 14

    Jun

  • 19

    Jun

  • 25

    Jun

  • 25

    Jul

CELG

Celgene

$77.49

-0.82 (-1.05%)

06:58
06/13/18
06/13
06:58
06/13/18
06:58
Periodicals
Celgene acknowledges own error in failed regulatory approval of MS drug, FT says »

Celgene admits it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

  • 13

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.